Evidence map›Paper›PMID 40463168›Full record

ArticlebioRxiv : the preprint server for biology2025

CD4

Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O'Connell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Shiney ChandragantiDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.ORCID 0009-0003-5643-6188
Caitlyn SamsDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Sarthak SahooDepartment of Bioengineering, Indian Institute of Science, Bangalore, 560012, India.
Brian FengDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Isabel O'ConnellDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Lynna LiDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Sunita NepalDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Siddhartha PulukuriDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Kimaya BakhleDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Prathapan ThiruWhitehead Institute for Biomedical Research, Cambridge, MA, 02142, USA.
Corina SimianWhitehead Institute for Biomedical Research, Cambridge, MA, 02142, USA.
George W BellWhitehead Institute for Biomedical Research, Cambridge, MA, 02142, USA.
Mohit Kumar JollyDepartment of Bioengineering, Indian Institute of Science, Bangalore, 560012, India.
Anushka DongreDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.ORCID 0000-0001-5688-1132

Funding

Potentiating the Efficacy of Immune Checkpoint Blockade by Targeting Epithelial-Mesenchymal Transition (EMT)-induced Immunosuppression in Breast CarcinomasK22CA255420 · NCI · CORNELL UNIVERSITY · PI DONGRE, ANUSHKA · 2022 to 2024
$684k
NCI NIH HHS K22 CA255420
6 · The paper itself

Abstract

Although immune checkpoint blockade therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial-mesenchymal plasticity leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal breast tumors to anti-CTLA4 immune checkpoint blockade therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in quasi-mesenchymal breast tumors sensitizes them to anti-CTLA4 immune checkpoint blockade therapy in a CD4

Identifiers

PMID40463168
PMCPMC12132553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.